What is Apellis Pharmaceuticals, Inc. (APLS)?

Apellis Pharmaceuticals, Inc. (APLS) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of APLS?

The current price of APLS is $41.03. Prices are updated in real time on Stocks360.

What is APLS's price-to-earnings (PE) ratio?

APLS's trailing twelve-month PE ratio is 38.71, based on current price and earnings per share data available on Stocks360.

What is APLS's market capitalization?

APLS's market capitalization is $5,252,712,954.00, placing it in the mid-cap tier.

Apellis Pharmaceuticals, Inc. (APLS)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$41.03

Market Cap

$5.25B

PE (TTM)

38.71

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-0.25

Day Range

$41.03 – $41.05

52-wk Range

$16.61 – $41.14

Avg Volume

N/A

Volume

28.64M

Apellis Pharmaceuticals, Inc. (APLS) is a publicly traded company in the Healthcare sector. Latest price: $41.03. Market cap $5.25B. Trailing PE 38.71. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-28 · $30.05 2026-05-15 · $41.03 (+36.54%)

Earnings

Most Recent

May 7, 2026

EPS $0.15 vs est. $-0.38

Beat by $0.53

Proprietary Signals

Signal snapshot temporarily unavailable.

About Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacoplan, is currently undergoing Phase III clinical evaluation. This advanced-stage therapy is being explored for its potential in treating geographic atrophy (GA), a form of age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria (PNH). Beyond this lead candidate, Apellis also offers EMPAVELI (a systemic formulation of pegcetacoplan), which is being developed for a range of indications: in hematology for cold agglutinin disease (CAD) and thrombotic microangiopathy associated with hematopoietic stem cell transplantation (HSCT-TMA); in nephrology for C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN); and in neurology for amyotrophic lateral sclerosis (ALS). Furthermore, Apellis boasts a diverse pipeline including APL-2006, a dual-action C3 and VEGF inhibitor designed for complement-me…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	38.71×
P/S (TTM)	4.75×
P/B	12.46×
PEG	0.07×
P/FCF (TTM)	139.04×
EV / EBITDA	29.54×
EV / Sales	4.81×
Earnings Yield	2.58%
Free Cash Flow Yield	0.72%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$5.32B
Revenue (TTM)	$1.11B
Net Income (TTM)	$135.38M
Free Cash Flow (TTM)	$80.77M
Net Debt	$69.03M
Working Capital	$744.57M
Gross Margin	90.12%
Operating Margin	14.95%
Net Margin	12.06%
Return on Equity	39.71%
Return on Invested Capital	18.11%